Leland Gershell Analyst PerformanceManaging Director at OppenheimerLeland Gershell is a stock analyst at Oppenheimer in the medical sector, covering 38 publicly traded companies. Over the past year, Leland Gershell has issued 39 stock ratings, including buy and hold recommendations. While full access to Leland Gershell's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Leland Gershell's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions. Analyst Rankings, Coverage, and Performance StatisticsAnalyst RankingSubscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeatAverage Return00.00% 12-Month ROISuccess Rate00.00% Profitable RatingsTotal Ratings126 Last 8 YearsBuy Recommendations89.43% 110 Buy RatingsCompanies Covered38 Unique Companies Ratings Distribution123RatingsDistribution of strong buy, buy, hold, and sell ratings by Leland Gershell.RatingPercentageCount Strong Buy0.0%0 ratings Buy89.4%110 ratings Hold8.9%11 ratings Sell1.6%2 ratingsOut of 123 total stock ratings issued by Leland Gershell at Oppenheimer, the majority (89.4%) have been Buy recommendations, followed by 8.9% Hold and 1.6% Sell.Best & Worst CallsBest Call0000.0%VERUSep 2020Subscribe to MarketBeat All Access to get analyst recommendation ROI.Worst Call000.0%CRXTQSep 2021Subscribe to MarketBeat All Access to get analyst recommendation ROI.Exchange CoverageExchangePercentageCountNASDAQ97.4% of companies on NASDAQ37 companiesOTCMKTS2.6% of companies on OTCMKTS1 companyLeland Gershell, an analyst at Oppenheimer, currently covers 38 companies listed on NASDAQ and OTCMKTS, with the majority traded on NASDAQ.Coverage FocusSector IconSectorPercentageMedical38 companies100.0%Leland Gershell of Oppenheimer specializes in stock coverage within the Medical sector.Coverage IndustriesIndustryPercentageMED - BIOMED/GENE20 companies52.6%MED - DRUGS9 companies23.7%PHARMACEUTICAL PREPARATIONS6 companies15.8%MED PRODUCTS2 companies5.3%MED - GENERIC DRG1 company2.6% About Leland GershellLeland Gershell is a Managing Director and Senior Analyst covering BioPharmaceuticals. Prior to joining Oppenheimer, Leland was Chief Financial Officer of Capricor Therapeutics and Tonix Pharmaceuticals. Leland also has both sell-side and buy-side experience and began his career on Cowen's biotechnology research team, where he provided sole coverage focused in the small and mid-cap segment. Leland has also authored numerous editorial and review articles and is an inventor on patents for Merck's Zolinza®. He earned his MD and Ph.D. in Organic Chemistry from Columbia University and his BA magna cum laude in Chemistry and Asian Studies from Dartmouth College.Follow on LinkedIn Leland Gershell's Ratings History at Oppenheimer Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe Start Date End Date All Ratings Strong Buy Buy Hold Sell Rating Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.Available with a MarketBeat All Access Subscription12-Month ROIUpgrade to All Access to use the All ROI Filter Export CompanyReport DateActionReport Date Price12-MonthPrice TargetRating12-MonthPrice & ROIDetailsVERUVeru5/15/2026Lower Price Target$2.08$24.00Outperform$0.0000.00% ROICRNXCrinetics Pharmaceuticals5/11/2026Lower Price Target$36.68$84.00Outperform$0.0000.00% ROIURGNUrogen Pharma5/7/2026Boost Price Target$26.25$40.00Outperform$0.0000.00% ROICLYMClimb Bio4/21/2026Boost Price Target$9.51$18.00Outperform$0.0000.00% ROIARGXargenex4/2/2026Lower Price Target$746.60$1,014.00Outperform$0.0000.00% ROISLNOSoleno Therapeutics3/18/2026Lower Price Target$33.43$80.00Outperform$0.0000.00% ROIOCGNOcugen3/11/2026Initiated Coverage$1.77$10.00Outperform$0.0000.00% ROIENGNenGene3/11/2026Lower Price Target$6.87$30.00Outperform$0.0000.00% ROITRVITrevi Therapeutics3/9/2026Reiterated Rating$11.79Outperform$0.0000.00% ROICALCCalciMedica3/5/2026Lower Price Target$0.62$10.00Outperform$0.0000.00% ROI Get the Latest News and Ratings for Your StocksEnter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. AARDAardvark Therapeutics3/2/2026Lower Price Target$5.52$21.00Outperform$0.0000.00% ROIBMRNBioMarin Pharmaceutical2/24/2026Lower Price Target$63.92$95.00Outperform$0.0000.00% ROIASNDAscendis Pharma A/S2/12/2026Boost Price Target$221.49$262.00Outperform$0.0000.00% ROIALNYAlnylam Pharmaceuticals1/7/2026Initiated Coverage$425.46$500.00Outperform$0.0000.00% ROISPRBSpruce Biosciences12/23/2025Initiated Coverage$82.82$283.00Outperform$0.0000.00% ROIAARDAardvark Therapeutics12/23/2025Initiated Coverage$14.55$35.00Outperform$0.0000.00% ROILXEOLexeo Therapeutics12/10/2025Reiterated Rating$9.51$20.00Outperform$0.0000.00% ROICAPRCapricor Therapeutics12/8/2025Boost Price Target$26.89$54.00Outperform$0.0000.00% ROIENGNenGene11/12/2025Reiterated Rating$8.82$33.00Outperform$0.0000.00% ROICPRXCatalyst Pharmaceuticals11/7/2025Reiterated Rating$20.99$33.00Outperform$0.0000.00% ROIXERSXeris Biopharma11/7/2025Reiterated Rating$7.44$18.00Outperform$0.0000.00% ROIRYTMRhythm Pharmaceuticals11/5/2025Downgrade$104.99Market Perform$0.0000.00% ROIALNYAlnylam Pharmaceuticals10/31/2025Reiterated Rating$449.56$500.00Outperform$0.0000.00% ROIXERSXeris Biopharma10/29/2025Boost Price Target$9.79$18.00Outperform$0.0000.00% ROIVRDNViridian Therapeutics10/21/2025Boost Price Target$24.57$36.00Outperform$0.0000.00% ROICRNXCrinetics Pharmaceuticals9/30/2025Boost Price Target$41.47$87.00Outperform$0.0000.00% ROITECXTectonic Therapeutic9/3/2025Initiated Coverage$16.65$80.00Outperform$0.0000.00% ROIVRDNViridian Therapeutics8/7/2025Boost Price Target$16.81$32.00Outperform$0.0000.00% ROISLNOSoleno Therapeutics8/7/2025Boost Price Target$80.36$110.00Outperform$0.0000.00% ROIBBIOBridgeBio Pharma8/6/2025Boost Price Target$49.21$61.00Outperform$0.0000.00% ROIALNYAlnylam Pharmaceuticals8/4/2025Upgrade$401.80$490.00Outperform$0.0000.00% ROILXEOLexeo Therapeutics7/31/2025Initiated Coverage$4.65$20.00Outperform$0.0000.00% ROIRYTMRhythm Pharmaceuticals7/10/2025Boost Price Target$88.42$110.00Outperform$0.0000.00% ROIBBIOBridgeBio Pharma7/9/2025Upgrade$43.19$60.00Outperform$0.0000.00% ROICAPRCapricor Therapeutics6/23/2025Lower Price Target$7.15$22.00Outperform$0.0000.00% ROIURGNUrogen Pharma6/13/2025Set Price Target$13.49$31.00Buy$0.0000.00% ROIASNDAscendis Pharma A/S6/13/2025Reiterated Rating$172.66$224.00Outperform$0.0000.00% ROICLYMClimb Bio6/6/2025Initiated Coverage$1.24$10.00Outperform$0.0000.00% ROIURGNUrogen Pharma6/3/2025Lower Price Target$4.96$10.00Outperform$0.0000.00% ROIXERSXeris Biopharma5/9/2025Boost Price Target$5.07$7.00Outperform$0.0000.00% ROIThe REAL Reason Trump is Invading Iran (Ad)For a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Because my research has led me to believe we’re risking World War 3 with Iran for a completely different reason.Click here to find out what it is.ARGXargenex5/9/2025Boost Price Target$554.89$708.00Outperform$000.0000.00% ROIQNCXQuince Therapeutics3/24/2025Initiated Coverage$13.80$100.00Outperform$0.0000.00% ROITRVITrevi Therapeutics3/11/2025Boost Price Target$5.87$20.00Outperform$00.0000.00% ROIARGXargenex2/28/2025Boost Price Target$619.04$704.00Outperform$000.0000.00% ROIBMRNBioMarin Pharmaceutical2/24/2025Upgrade$68.25$98.00Outperform$00.0000.00% ROI Stock Forecasts and Research Tools Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Price Forecasts for Popular Stocks Alphabet (Google) Stock ForecastAmazon Stock ForecastApple Stock ForecastMeta (Facebook) Stock ForecastMicrosoft Stock ForecastNetflix Stock ForecastNvidia Stock ForecastTesla Stock Forecast Top Stock Recommendations by BrokerageMorgan StanleyJefferies Financial GroupStifel NicolausOppenheimerBerenberg BankRoth MkmWall Street ZenUBS GroupCitigroupBarclaysWells Fargo & CompanyRoyal Bank Of CanadaJPMorgan Chase & Co.The Goldman Sachs GroupTD Cowen Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
